Medroxyprogesterone Acetate (MPA) / Megestrol Acetate (Hormonal Therapy)
Treatment for Uterine cancer
Typical Dosage: MPA 400-600mg daily, Megestrol Acetate 160mg 2-4 times daily
Effectiveness
35%
Safety Score
60%
Clinical Trials
40
Participants
5K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
MPA 400-600mg daily, Megestrol Acetate 160mg 2-4 times daily
Time to Effect
1-3 months
Treatment Duration
6-12 months or longer for recurrent disease
Evidence Quality
MODERATEConfidence Score
75%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$300
Monitoring:$2,000
Side Effect Mgmt:$200
Total Annual:$2,500
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$12,500/QALY
QALYs Gained
0.2
Outcome-Based Costs
Cost per Responder
$6,250
Cost per Remission
$10,000
Medroxyprogesterone Acetate (MPA) / Megestrol Acetate (Hormonal Therapy) Outcomes
for Uterine cancer
Efficacy Outcomes
Overall Effectiveness
+35%
Response Rate
+40%
Remission Rate
+25%
Common Side Effects
Weight gain
+40%
Fluid retention
+30%
Hot flashes
+25%
Mood changes
+15%
Increased risk of venous thromboembolism
+7%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
1 active trial recruiting for Medroxyprogesterone Acetate (MPA) / Megestrol Acetate (Hormonal Therapy) in Uterine cancer
SHAPE-ENDO: Multimodal Pre-Surgical Optimization in Patients With Obesity and Early-Stage Endometrial Cancer (Phase 1)
NCT07462663NOT YET RECRUITING
82 participants
OBSERVATIONAL
Started: Sep 1, 2026